



Natural Cycles^o

Natural Cycles Closes \$55m Series C Financing Round Led by Lauxera Capital Partners

Stockholm (Sweden), San Francisco (US), Paris (France), May 29, 2024 - [Natural Cycles](#), a leading women's health company that developed the world's first birth control app, announced today the closure of its Series C financing round led by Lauxera Capital Partners. The \$55 million financing with participation from Point72 Private Investments and a revolving debt facility from J.P. Morgan, will be used to invest in commercial acceleration, new product development, and healthcare reimbursement automation.

Founded in 2013 by Dr. Elina Berglund Scherwitzl and Dr. Raoul Scherwitzl, Natural Cycles developed the first direct-to-consumer contraceptive app that has been used by more than three million users worldwide. It remains the only digital form of birth control on the market cleared by regulators in the United States (FDA), Europe (TÜV SÜD), Canada (Health Canada), Australia (TGA), Singapore (HSA), and South Korea (MFDS).

"We've experienced profitable growth over the last few years as women actively seek more birth control options and we're excited to welcome the next phase of Natural Cycles journey together with Lauxera Capital Partners and Point72 Private Investments," said Dr. Raoul Scherwitzl, co-founder, and CEO of Natural Cycles. *"We look forward to leveraging their expertise to fulfill Natural Cycles' mission of making hormone-free birth control more accessible and combining technology and science to fill the gaps in underserved areas of women's health."*

Earlier this month Natural Cycles launched NC^o Postpartum, an innovative experience within the Natural Cycles app specifically tailored to help guide new moms recovering physically and mentally from childbirth. NC^o Postpartum builds on the other three modes already available within the Natural Cycles app – NC^o Birth Control, NC^o Plan Pregnancy, and NC^o Follow Pregnancy – providing users with support throughout their fertility journey.

"Our mission at Lauxera is to partner with ambitious entrepreneurs transforming the future of medicine with unique technology. The visionary Natural Cycles team has built an exceptional company delivering profitable growth supported by unique clinical and regulatory business moats," said Samuel Levy, founding partner of Lauxera Capital Partners. *"We are delighted to partner with Elina, Raoul and their team to offer women an alternative to traditional approaches without the side effects and compromises."*



Natural Cycles^o

As part of the investment, Levy will join Natural Cycles' Board of Directors.

Lauxera Capital Partners and Point72 Private Investments join Natural Cycles' current distinguished investors, which include EQT Ventures, Samsung Ventures, Heartcore Capital, Headline, and Bonnier Ventures.

About Natural Cycles^o

Founded in 2013 by Dr. Elina Berglund Scherwitzl and Dr. Raoul Scherwitzl, Natural Cycles is a leading women's digital health company that developed the world's first birth control app. As a medical device, the NC^o app is cleared by the FDA in the United States and certified to be used as a contraceptive in the UK, Canada, Australia, Singapore, and South Korea. The NC^o app is powered by an algorithm that uses body temperature to determine each user's daily fertility status. Users can manually take their body temperature with a thermometer or sync overnight temperature trend data from an Oura Ring or Apple Watch when they wake up. For more information, visit naturalcycles.com.

About Lauxera Capital Partners

Founded in January 2020, Lauxera Capital Partners is an independent asset management company based in France (Paris) and in the United States (San Francisco). Lauxera is a healthcare specialist investor working to promote the growth of European Healthtech companies. Its first fund, Lauxera Growth I, was reserved for professional investors and obtained the French government's "Tibi" label within the framework of the institutional investors' charter for the financing of technology companies. Led by a team of life sciences business builders and professional healthcare investors with more than 50 years experience, Lauxera aims to support the international commercial expansion of Europe's most promising Healthtech innovations.

More information at: <https://lauxera.com>

Press contacts:

Ulysse Communication

Bruno ARABIAN

+33 (0) 6 87 88 47 26 / barabian@ulyse-communication.com

Laurent WORMSER

+33 (0)6 13 12 04 04 / lwormser@ulyse-communication.com